EU’s Innovative Drug Approval Tally Shows Sharp Decline
Just 36 Products With New Active Substances Got The All-Clear In 2023
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
